US 7,732,594 B2 · Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression

Abstract

The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.

Claims1

Dependent claims

A suppression reagent that is a DSG3-RNAi plasmid for injecting into cancer individuals, wherein the DSG3-RNAi plasmid is a DSG3-RNAi sequence and the DSG3-RNAi sequence that act on DSG3 mRNA is 5′-TTGTTAAGTGCCAGACTT-3′(SEQ. ID. NO. 2) to synthesize two clones of DSG3-RNAi sequences in the structure of symmetrical and then link the synthesized sequence into an expression vector.

Dependencies are inferred from the claim text.

Facts

Application

12/405,548Filed 17 Mar 2009 · division

Priority

6 Nov 2006

Published

US 2009/0029354 A117 Sep 2009

Granted

8 Jun 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

G01N 33/57557
For cancer: of other specific parts of the body, e.g. brain
C12N 15/1138
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against…
C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
C12N 2310/111
Antisense: spanning the whole gene, or a large part of it

Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression

Life of this patent

Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression

Life of this patent

Abstract

Claims1